From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.
From Business Of Biotech · · 55 min
This plays from the publisher's own server. We do not host a copy.
Description
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new)
On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real RNA-targeting medicines, and why Ionis stuck with a difficult modality despite multiple setbacks. Brett describes the company's shift from a partner-first model to building a wholly-owned pipeline, commercial function, and an expanded manufacturing operation, and how he as a founding scientist-turned-CEO bridged a skills gap in finance and investor relations.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/).
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/